Jpmorgan Chase & CO Regeneron Pharmaceuticals, Inc. Call Options Transaction History
Jpmorgan Chase & CO
- $1.1 Trillion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding REGN
# of Institutions
1,424Shares Held
82.1MCall Options Held
835KPut Options Held
1.46M-
Vanguard Group Inc Valley Forge, PA8.93MShares$9.39 Billion0.17% of portfolio
-
Black Rock Inc. New York, NY8.57MShares$9.01 Billion0.19% of portfolio
-
State Street Corp Boston, MA4.84MShares$5.09 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.65MShares$4.89 Billion0.76% of portfolio
-
Capital International Investors Los Angeles, CA3.13MShares$3.29 Billion0.62% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $113B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...